|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
William Beaumont Hospitals Medtronic BRC |
|---|---|
| Information provided by: | William Beaumont Hospitals |
| ClinicalTrials.gov Identifier: | NCT00401882 |
Purpose
The purpose of this research study is to evaluate the effectiveness of metoprolol, a "beta blocker," in treating patients in the hospital with a cardiac arrest. It will be given intravenously (given into a vein).
The subjects who will take part in this study are 18 years of age or older, are experiencing a cardiac arrest in the hospital, and are in a life threatening situation. Patients who develop a cardiac arrest require prompt electrical defibrillation (electrical shocks) to restore the normal beating rhythm of the heart. In patients who do not respond to electrical defibrillation, current standard of care recommends the use of medications which have been shown to be of unknown benefit. Some people recover from a cardiac arrest, but many people do not. We want to learn whether giving metoprolol will improve survival of patients with a cardiac arrest. A total of 100 patients will be enrolled in the study. Patients will receive either the standard of care with the drug epinephrine or the standard of care plus metoprolol.
| Condition | Intervention | Phase |
|---|---|---|
|
Cardiac Arrest Sudden Cardiac Death Ventricular Fibrillation Tachycardia, Ventricular |
Drug: Metoprolol |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial |
| Estimated Enrollment: | 100 |
| Study Start Date: | January 2007 |
| Estimated Study Completion Date: | November 2009 |
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: David Haines, MD | 248-898-4198 | dhaines@beaumont.edu |
| United States, Michigan | |
| William Beaumont Hospital | Recruiting |
| Royal Oak, Michigan, United States, 48073 | |
| Contact: David Haines, MD 248-898-4198 dhaines@beaumont.edu | |
| Principal Investigator: david Haines, MD | |
| Principal Investigator: | David E Haines, MD | William Beaumont Hospitals |
More Information
| Responsible Party: | Beaumont Hospitals ( David Haines ) |
| Study ID Numbers: | 2006-008 |
| Study First Received: | November 17, 2006 |
| Last Updated: | July 23, 2009 |
| ClinicalTrials.gov Identifier: | NCT00401882 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Cardiac arrest Sudden Cardiac Death Ventricular Fibrillation Pulseless Ventricular Tachycardia Cardiopulmonary resuscitation |
|
Neurotransmitter Agents Death Heart Diseases Adrenergic Agents Tachycardia Heart Arrest Cardiovascular Agents Antihypertensive Agents Metoprolol Paroxysmal Ventricular Fibrillation Shock |
Metoprolol succinate Death, Sudden Adrenergic beta-Antagonists Adrenergic Antagonists Peripheral Nervous System Agents Anti-Arrhythmia Agents Death, Sudden, Cardiac Tachycardia, Ventricular Ventricular Fibrillation Arrhythmias, Cardiac |
|
Death Neurotransmitter Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Pathologic Processes Therapeutic Uses Adrenergic beta-Antagonists Cardiovascular Diseases Death, Sudden, Cardiac Anti-Arrhythmia Agents Tachycardia, Ventricular Ventricular Fibrillation |
Sympatholytics Heart Diseases Tachycardia Heart Arrest Cardiovascular Agents Metoprolol Antihypertensive Agents Pharmacologic Actions Autonomic Agents Death, Sudden Adrenergic Antagonists Peripheral Nervous System Agents Arrhythmias, Cardiac |
